SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Heartflow, Inc. (HTFL) News

Follow Heartflow, Inc. (HTFL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol HTFL Asset equity Sector Markets 90 days 11 Last 46.745 Updated Nov 12, 2026, 11:03 PM UTC Open live news feed Open HTFL chart & news
M HeartFlow Reports Q3 Revenue of $72.9 Million, Raises 2026 Guidance Revenue rose 57% year over year to $72.9 million. HeartFlow raised full-year revenue guidance to $262 million-$264 million; quarterly adjusted loss was $0.03 per share. EQUITY | Nov 12, 2026, 11:03 PM UTC M Heartflow Reports Q3 2026 Results, Raises Full-Year Guidance EQUITY | Nov 12, 2026, 09:22 PM UTC M HeartFlow Q3 Adjusted Loss Narrows as Revenue Rises; 2026 Guidance Raised HeartFlow reported a narrower adjusted loss and higher revenue for Q3 and raised its 2026 revenue guidance. EQUITY | Nov 12, 2026, 09:19 PM UTC M Heartflow CT-Guided PCI Planning Meets P4 Trial Primary Endpoint Heartflow said its CT-guided PCI planning met the primary endpoint in the P4 trial. EQUITY | Nov 02, 2026, 10:50 AM UTC M Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7% EQUITY | Oct 06, 2026, 07:52 AM UTC L HTFL: Plaque Analysis growth and new trials drive expansion toward an $11B TAM by 2030 AI-driven coronary artery disease diagnostics are accelerating growth, with Plaque Analysis adoption and revenue surging, supported by robust clinical data and expanding payer coverage. Strategic RCTs target a $6B asympt EQUITY | Sep 09, 2026, 09:39 PM UTC L HTFL: Rapid Plaque Analysis growth and new trials target a doubling of addressable market by 2029 AI-driven coronary artery disease diagnostics are seeing rapid Plaque Analysis adoption, strong revenue growth, and expanding clinical evidence. New RCTs target a $6 billion asymptomatic market, aiming to double TAM by 2 EARNINGS | Sep 09, 2026, 09:04 PM UTC L Heartflow price target announced at $55.00 by UBS UBS set a price target of $55.00 per share for Heartflow. EQUITY | Sep 09, 2026, 01:33 PM UTC H HTFL - Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart HTFL - Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half GEOPOLITICS | Aug 28, 2026, 06:57 AM UTC L Heartflow to participate in Wells Fargo healthcare conference Heartflow will participate in the Wells Fargo 21st Annual Healthcare Conference. EQUITY | Aug 27, 2026, 08:08 PM UTC L HTFL - Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference HTFL - Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference EQUITY | Aug 27, 2026, 08:01 PM UTC L HeartFlow shares jump after strong Q2 adjusted EPS, raised outlook HeartFlow Inc. (HTFL) posts better-than-expected second-quarter adjusted EPS and raises full-year 2026 revenue guidance to $246 million–$250 million from $228 million–$232 million. EARNINGS | Aug 14, 2026, 07:47 PM UTC L Heartflow, Eton, Nu Holdings rise on earnings and guidance Heartflow shares jump after quarterly adjusted EPS beats estimates while revenue misses; Eton Pharmaceuticals and Nu Holdings also climb after better-than-expected quarterly results, and Eton issues FY26 revenue guidance EARNINGS | Aug 14, 2026, 01:55 PM UTC L HeartFlow raises full-year revenue and margin guidance after Q2 growth HeartFlow reported Q2 2026 revenue of $64.1 million, up 48% year over year, and raised full-year revenue guidance to $246 million-$250 million while lifting non-GAAP gross margin guidance to about 82%. EARNINGS | Aug 13, 2026, 09:49 PM UTC L HeartFlow raises FY2026 sales guidance to $246M–$250M HeartFlow (NASDAQ: HTFL) raises FY2026 sales guidance to $246.000M–$250.000M from $218.000M–$222.000M versus a $230.073M estimate. EARNINGS | Aug 13, 2026, 08:01 PM UTC L Heartflow reports Q2 2026 results and raises full-year 2026 guidance Heartflow (HTFL) reports second-quarter 2026 financial results and raises its full-year 2026 guidance, according to TradeXchange Newsdesk. EARNINGS | Aug 13, 2026, 08:01 PM UTC H Cantor Initiates DUOT Overweight Banks initiate coverage on several stocks EQUITY | Jul 31, 2026, 11:38 AM UTC L Freedom Capital Markets Initiates Coverage On HeartFlow with Buy Rating, Announces Price Target of $37 Freedom Capital Markets analyst Gene Mannheimer initiates coverage on HeartFlow (NASDAQ: HTFL ) with a Buy rating and announces Price Target of $37. EQUITY | Jul 01, 2026, 08:45 AM UTC